In line with our in vitro findings, AIM+ memory CD8 T cells from RA patients treated with JAKis incorporated significantly less puromycin than those from HD or RA patients treated with MTX (Fig. 6D). This evidence concerns the gene CD8A and rheumatoid arthritis.